
Movano-Corvex Healthcare Tech Merger Faces 40-60% Rejection Risk as US Regulators Tighten Global M&A Scrutiny
Movano Inc.'s all-stock merger with Corvex faces medium-probability regulatory rejection as US authorities intensify healthcare technology deal reviews. The deal enters an environment where FTC and SEC rejection rates for health tech M&A doubled to 23% in 2024-2025, mirroring tighter merger controls in EU and Asia-Pacific markets.




